> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CytoDyn Seeks Fast Track for Leronlimab in Breast Cancer
- URL: https://www.fdaweb.com/cytodyn-seeks-fast-track-for-leronlimab-in-breast-cancer/
- Published: 2019-03-11T12:00:00.000Z
- Updated: 2026-09-15T01:11:18.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143573

CytoDyn says it is seeking fast track status for its humanized CCR5 monoclonal antibody, leronlimab (PRO 140), after it showed a significant reduction in the volume of human breast cancer tumor metastasis in a murine xenograft model. “The metastatic tumor volume was reduced by more than 98% after seven weeks,” the company says. The agency recently cleared CytoDyn’s IND application to initiate a Phase 1b/2 study for the addition of leronlimab to existing therapies for metastatic triple-negative breast cancer.